Nov 5
TRLV · Trulieve Cannabis Corp.
Market Cap
$1.97B
Shares
170.63M
Volume · Nov 6
1.55M
Avg daily vol (3M)
1.76M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$11.56
Open$10.95
Day$10.77–11.65
52W close$4.76–13.00
Avg vol 30d1.7M
Short int7.3M · 4.3% of shares · 4.5d
Short vol55%
Last earningsNov 5, 2026
DataJan 2020–Nov 2026
Filing10-Q · Nov 5
Up next
Jan 31, 2027
Est · unconfirmed
· in 12 wks
Latest documents
2026
Nov 5
Quarterly report
10-Q
FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3
AI summary on its way
Revenue $230.22M
▼ 20.1%
Net income $774K
Diluted EPS $0.00
Nov 5
Aug 11
Current report
8-K
Entered into a material agreement, Unregistered sale of equity, Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change
AI summary on its way
Aug 7
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.08B
Trailing 12 months
Net income (TTM)
−$446.60M
Trailing 12 months
Revenue growth YoY
-20.1%
Year over year
Operating margin
-25.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$130.68M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.9%
Year over year · more shares
Price change (1Y)
+61.0%
Trailing year
Short interest
4.3%
Latest settlement · 4.5 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26
TL;DR. Medical-only third-quarter revenue grew 4%, gross margin reached 64%, adjusted EBITDA was $89 million, Georgia is scaling rapidly, and the company expects fourth-quarter revenue growth and at least $225 million of 2026 operating cash flow. Risks include a fourth-quarter net loss, holiday margin pressure, higher planned capital expenditures, a $625 million tax-position liability, pending Texas licensure, and weaker nine-month reported results.
Bullish
- + Federal rescheduling delivered DEA registration and eliminated the punitive 280E tax burden from medical operations.
- + The NYSE listing and index inclusions expanded trading volume, institutional access, and passive investor demand.
- + Fourth-quarter revenue is expected to increase by a low single-digit percentage from third-quarter levels.
Bearish
- − Management expects a fourth-quarter net loss from purchase-accounting adjustments related to the Harvest deconsolidation.
- − Fourth-quarter gross margin is expected to face pressure from holiday promotions.
- − The 2026 capital-expenditure plan was raised to approximately $105 million from $95 million to fund growth-market investments.
- − The balance sheet carried a $625 million uncertain tax position, including $610 million related to the 280E challenge.
- − Texas commercialization remains dependent on converting the conditional license into a final license.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 28.2 · fear
Equity put/call 0.89
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+30%
above
Price vs 50-day avg
+3%
above
RSI (14)
57
neutral
MACD trend
Positive
52-week position
83%
mid-range
Momentum
relative strength
1-month return
+8%
trailing
6-month return
+44%
trailing
YTD return
+33%
this year
Relative strength
+45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
73 of 128 funds reported for Sep 30 · net +738.2K sh shares · +22 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.25% of shares out · ▲ +12.8% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
128 holders — near 3-yr high, broad support
Squeeze score
74
high risk · 0–100
Fundamentals
Revenue growth
−0%
Y/Y
Gross margin
60%
contracting
EPS growth
+27%
Y/Y
Free cash flow
$228.6M
Buyback
$50.0M
authorized
Balance sheet
$118.8M
net cash
Quant / Vol
risk profile
Volatility
110%
annualized · 1-yr
Max drawdown
−54%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 7, 2026
third quarter
Gross margin
63%
full year 2026
Operating cash flow
Initiated
at least $225M
Capital expenditures
$95M
Previous outlook
earlier release
· from the 8-K filed May 7, 2026
Still-open targets the latest release did not restate under the same label.
Cash flow from operations
· 2026
at least $250M
Capital expenditures
· 2026
up to $85M
Guided vs delivered
· last 1 settled
Revenue
2022
guided $1.25B – $1.3B
$1.22B
Miss −4.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+30%
Bullish
Price vs 50-day avg
+3%
Bullish
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
83%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $11 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
73 of 128 funds reported for Sep 30 · net +738.2K sh shares · +22 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.25% of shares out · ▲ +12.8% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
128 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $12 · 83%
Range high $13
vs 200-day avg +30%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $98M | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA (Non-GAAP) % of Revenue non-GAAP | 36.2% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TRLV
this stock
Trulieve Cannabis Corp.
|
$1.97B | +33.0% | -0.4% | — | 4.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$67.16B | +34.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$55.28B | +12.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$49.72B | +36.5% | +4.3% | 96.8 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TRLV | +12.5% | +8.3% | +44.1% | +12.5% | +33.0% |
| SPY | -2.7% | -5.6% | -0.5% | -2.7% | +7.8% |
| vs SPY | +15.2% | +13.9% | +44.6% | +15.2% | +25.2% |
Capital returns
Buyback program
· as of Aug 7, 2026
Authorized
$50.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1754195
CUSIP
89790E106
13F (30d)
63 filings
63 filers
Visit website
Investor relations